Chapter title |
An HTRF® Assay for the Protein Kinase ATM
|
---|---|
Chapter number | 4 |
Book title |
ATM Kinase
|
Published in |
Methods in molecular biology, January 2017
|
DOI | 10.1007/978-1-4939-6955-5_4 |
Pubmed ID | |
Book ISBNs |
978-1-4939-6953-1, 978-1-4939-6955-5
|
Authors |
Phillip Adams, Jonathan Clark, Simon Hawdon, Jennifer Hill, Andrew Plater |
Editors |
Sergei V. Kozlov |
Abstract |
Ataxia telangiectasia mutated (ATM) is a serine/threonine kinase that plays a key role in the regulation of DNA damage pathways and checkpoint arrest. In recent years, there has been growing interest in ATM as a therapeutic target due to its association with cancer cell survival following genotoxic stress such as radio- and chemotherapy. Large-scale targeted drug screening campaigns have been hampered, however, by technical issues associated with the production of sufficient quantities of purified ATM and the availability of a suitable high-throughput assay. Using a purified, functionally active recombinant ATM and one of its physiological substrates, p53, we have developed an in vitro FRET-based activity assay that is suitable for high-throughput drug screening. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 7 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 2 | 29% |
Researcher | 2 | 29% |
Student > Master | 1 | 14% |
Unknown | 2 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 2 | 29% |
Agricultural and Biological Sciences | 2 | 29% |
Chemistry | 1 | 14% |
Unknown | 2 | 29% |